Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
News|Articles|June 1, 2024
Psychedelics Utilization Poll
Author(s)Psychiatric Times Editors
Answer a quick question about psychedelics!
Advertisement
If approved by the FDA, would you be interested in delivering psychedelics to patients?
Advertisement
Related to this article
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
2
FDA Shelves Fast-Track Drug Review Initiative
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Oveporexton Now Available: First and Only Orexin Agonist for Narcolepsy Type 1
5